Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
4/28/2026, 12:00:00 AM
On April 28, 2026, the U.S. FDA's CDER proposed to withdraw the approval for Amgen's drug Tavneos due to effectiveness and safety concerns. High importance is estimated as drug withdrawals significantly impact revenue and reputation.
Korean Translation
2026년 4월 28일, 미국 FDA CDER이 효능 및 안전성 우려를 이유로 타브네오스(Tavneos)의 승인 철회를 제안함. 품목 허가 취소는 매출 및 기업 신뢰도에 중대한 영향을 미치므로 높은 중요도로 예상함.
Related Recent Events
Procter & Gamble Co (The) (PG) · Earnings Release
Analysts forecast Procter & Gamble to release its Q4 2026 earnings report on August 4, 2026, forecasted. Low impact is estimated as the announcement date itself typically has minimal immediate price effect.
8/4/2026, 12:00:00 AM
Kforce Inc (KFRC) · Other
Quarterly dividend of $0.40 per share, ex-dividend date is June 12, 2026 scheduled
6/12/2026, 12:00:00 AM
DICK'S Sporting Goods Inc (DKS) · Earnings Release
Medium importance is estimated due to the historical impact of quarterly earnings on stock volatility. Q1 2026 earnings release is scheduled.
5/27/2026, 12:00:00 AM
Booz Allen Hamilton Holding Corporation (BAH) · Earnings Release
Fourth quarter and full fiscal year 2026 earnings results for the period ending March 31, 2026 are scheduled.
5/22/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Other
The Annual Meeting of Shareholders is scheduled for May 21, 2026. Low importance estimated as annual meetings typically result in 1-5% price impact, scheduled.
5/21/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Target is scheduled to release its Q1 2026 earnings on May 20, 2026. Analysts forecast EPS of approximately $1.34. This is a future event, and importance is estimated as High due to the potential for significant price movement based on results and updated guidance scheduled
5/20/2026, 12:00:00 AM